Multiple Dimensions of Using Mesenchymal Stem Cells for Treating Liver Diseases: from Bench to Beside.
Lijun Chen,Ning Zhang,Yuqi Huang,Qi Zhang,Yangxin Fang,Jiamin Fu,Yin Yuan,Lu Chen,Xin Chen,Zhenyu Xu,Yifei Li,Hiromi Izawa,Charlie Xiang
DOI: https://doi.org/10.1007/s12015-023-10583-5
2023-01-01
Stem Cell Reviews and Reports
Abstract:Liver diseases impose a huge burden worldwide. Although hepatocyte transplantation has long been considered as a potential strategy for treating liver diseases, its clinical implementation has created some obvious limitations. As an alternative strategy, cell therapy, particularly mesenchymal stem cell (MSC) transplantation, is widely used in treating different liver diseases, including acute liver disease, acute-on-chronic liver failure, hepatitis B/C virus, autoimmune hepatitis, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, alcoholic liver disease, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. Here, we summarize the status of MSC transplantation in treating liver diseases, focusing on the therapeutic mechanisms, including differentiation into hepatocyte-like cells, immunomodulating function with a variety of immune cells, paracrine effects via the secretion of various cytokines and extracellular vesicles, and facilitation of homing and engraftment. Some improved perspectives and current challenges are also addressed. In summary, MSCs have great potential in the treatment of liver diseases based on their multi-faceted characteristics, and more accurate mechanisms and novel therapeutic strategies stemming from MSCs will facilitate clinical practice.